Impact of the COVID-19 pandemic on community antibiotic consumption in the EU/European Economic Area: a changepoint analysis
Open Access
- 6 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (10) , 2572-2580
Abstract
Objectives: A decrease in community antibiotic consumption in Europe has been observed during the COVID-19 pandemic. The magnitude of this decrease, how fast after the outbreak it occurred, whether it was sustained during the pandemic and whether the seasonal variation in antibiotic consumption was affected, have not yet been evaluated in detail. Methods: Data on community antibiotic consumption were available from the European Surveillance of Antimicrobial Consumption Network for 28 EU/European Economic Area (EEA) countries between 2010 and 2021. Antibiotic consumption was expressed as DDDs per 1000 inhabitants per day (DID). The impact of the pandemic on antibiotic consumption was investigated using descriptive statistics and non-linear mixed changepoint models for quarterly and yearly data. Results: The decrease in overall antibiotic consumption between 2019 and 2020 (−3.4 DID; −18.6%) was mainly due to a decrease in the consumption of penicillins [Anatomical Therapeutic Chemical (ATC) code J01C] (−1.9 DID; −23.0%), other β-lactam antibacterials (J01D) (−0.6 DID; −25.8%) and macrolides, lincosamides and streptogramins (J01F) (−0.5 DID; −17.4%) and was sustained during 2021. The changepoint analysis of yearly data (28 countries) estimated a decrease of 3.3 DID in overall antibiotic consumption (J01) between 2019 and 2020. The analysis of quarterly data (16 countries) estimated a decrease in overall antibiotic consumption (J01) of 4.0 DID and a decrease in seasonal variation of 1.2 DID between the first and second quarters of 2020. Conclusions: The changepoint analysis indicated a significant, sudden and steep decrease in community antibiotic consumption in the EU/EEA immediately after the start of the COVID-19 outbreak in Europe, as well as a decrease in its seasonal variation.Keywords
Funding Information
- University of Antwerp
This publication has 30 references indexed in Scilit:
- Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?International Journal of Antimicrobial Agents, 2020
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: a randomized, placebo-controlled studyJournal of Antimicrobial Chemotherapy, 2016
- Antibiotic consumption and resistance: results of the SPIN-UTI project of the GISIO-SItI.2015
- Exploring the association between resistance and outpatient antibiotic use expressed as DDDs or packagesJournal of Antimicrobial Chemotherapy, 2015
- A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistanceBMC Infectious Diseases, 2014
- Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in TaiwanBMC Infectious Diseases, 2014
- Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled studyThe Lancet, 2007
- Outpatient antibiotic use in Europe and association with resistance: a cross-national database studyThe Lancet, 2005
- Bayesian Measures of Model Complexity and FitJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002